Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer

Authors:

Abstract
177Lu-vipivotide tetraxetan is a radiopharmaceutical that selectively targets prostate-specific membrane antigen (PSMA) and delivers beta-radiations to kill prostate cancer cells.Extensive experien...
Funding Information
  • funding

This publication has 84 references indexed in Scilit: